While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …

The future of ViiV Healthcare’s HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around £2 billion ($2.65 billion) …